BGI Genomics Co Ltd (300676) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BGI Genomics Co Ltd (300676) has a cash flow conversion efficiency ratio of 0.000x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-3.08 Million ≈ $-451.41K USD) by net assets (CN¥9.37 Billion ≈ $1.37 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BGI Genomics Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how BGI Genomics Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does BGI Genomics Co Ltd carry for a breakdown of total debt and financial obligations.
BGI Genomics Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BGI Genomics Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OneStream, Inc. Class A Common Stock
NASDAQ:OS
|
0.009x |
|
Santos Brasil Participações S.A
SA:STBP3
|
0.495x |
|
Home Product Center Public Company Limited
BK:HMPRO
|
0.023x |
|
Meshek Energy-Renewable Energies Ltd
TA:MSKE
|
0.010x |
|
Triputra Agro Persada Tbk PT
JK:TAPG
|
0.103x |
|
West African Resources Ltd
AU:WAF
|
0.055x |
|
RH
NYSE:RH
|
39.407x |
|
Delek US Energy Inc
NYSE:DK
|
0.925x |
Annual Cash Flow Conversion Efficiency for BGI Genomics Co Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of BGI Genomics Co Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see BGI Genomics Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥9.27 Billion ≈ $1.36 Billion |
CN¥95.72 Million ≈ $14.01 Million |
0.010x | -74.73% |
| 2023-12-31 | CN¥10.00 Billion ≈ $1.46 Billion |
CN¥408.77 Million ≈ $59.82 Million |
0.041x | +206.31% |
| 2022-12-31 | CN¥10.22 Billion ≈ $1.50 Billion |
CN¥136.38 Million ≈ $19.96 Million |
0.013x | -94.91% |
| 2021-12-31 | CN¥9.44 Billion ≈ $1.38 Billion |
CN¥2.48 Billion ≈ $362.34 Million |
0.262x | -56.13% |
| 2020-12-31 | CN¥6.03 Billion ≈ $881.76 Million |
CN¥3.60 Billion ≈ $527.19 Million |
0.598x | +1073.36% |
| 2019-12-31 | CN¥4.40 Billion ≈ $644.01 Million |
CN¥224.25 Million ≈ $32.82 Million |
0.051x | +1375.28% |
| 2018-12-31 | CN¥4.25 Billion ≈ $622.25 Million |
CN¥14.69 Million ≈ $2.15 Million |
0.003x | -93.51% |
| 2017-12-31 | CN¥4.26 Billion ≈ $623.07 Million |
CN¥226.57 Million ≈ $33.15 Million |
0.053x | -21.51% |
| 2016-12-31 | CN¥3.45 Billion ≈ $505.22 Million |
CN¥234.07 Million ≈ $34.25 Million |
0.068x | -34.62% |
| 2015-12-31 | CN¥3.17 Billion ≈ $463.80 Million |
CN¥328.68 Million ≈ $48.10 Million |
0.104x | +1961.44% |
| 2014-12-31 | CN¥1.47 Billion ≈ $214.45 Million |
CN¥-8.16 Million ≈ $-1.19 Million |
-0.006x | -109.08% |
| 2013-12-31 | CN¥597.94 Million ≈ $87.50 Million |
CN¥36.70 Million ≈ $5.37 Million |
0.061x | -87.27% |
| 2012-12-31 | CN¥150.37 Million ≈ $22.00 Million |
CN¥72.49 Million ≈ $10.61 Million |
0.482x | -- |
About BGI Genomics Co Ltd
BGI Genomics Co., Ltd. engages in the provision of genomic sequencing services and proteomic services to academic institutions, pharmaceutical companies, health care providers and other organizations in China and internationally. The company offers DNA sequencing services covering whole genome sequencing, plant/animal whole genome sequencing, exome sequencing, de novo sequencing, and metagenomic … Read more